Literature DB >> 28452906

Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease.

Chih-Wei Hsu1, Yu Lee, Chun-Yi Lee, Pao-Yen Lin.   

Abstract

Pisa syndrome (PS) is a state of dystonic muscle contraction with a marked truncal deviation to one side. It is an uncommon adverse effect of antipsychotic drugs, but is rarely reported in patients receiving acetylcholinesterase inhibitors, especially rivastigmine. We present a 57-year-old female patient with Alzheimer disease who began to develop symptoms of dementia at the age of 51 years. She was observed to have symptoms of PS after continuous use of rivastigmine (9 mg/d) for nearly 2 years. The PS symptoms improved after the dose of rivastigmine was reduced but recurred when the dose was added back to 9 mg/d. Finally, after we decreased the dose to 4.5 mg/d, her PS symptoms were remitted. This report reminds us that clinicians need to be cautious about the risk of PS when prescribing rivastigmine in a patient with early-onset Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28452906     DOI: 10.1097/WNF.0000000000000215

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  2 in total

Review 1.  An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine.

Authors:  Rita Khoury; Jayashree Rajamanickam; George T Grossberg
Journal:  Ther Adv Drug Saf       Date:  2018-01-08

2.  Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report.

Authors:  Yu Mimura; Shin Kurose; Taketo Takata; Hajime Tabuchi; Masaru Mimura; Michitaka Funayama
Journal:  BMC Neurol       Date:  2020-05-13       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.